Endo
As of the edition of 20 October 2026, Endo runs 28 drugs, 23 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 5 company names in this family.
- JHP Pharmaceuticals LLC: acquired in 2014; successor Endo International plc
- Endo Operations Ltd: acquired in 2024; successor Endo International plc
Drugs by status
| Status | Count |
|---|---|
| Marketed | 23 |
| Active | 2 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 28 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Buprenorphine | Ends 2028 (exclusivity) | 9 |
| Epinephrine | none listed | 23 |
| Ondansetron | none listed | 0 |
| Metronidazole | none listed | 0 |
| Testosterone | none listed | 4 |
| Cyanocobalamin | none listed | 0 |
| Megestrol acetate | none listed | 0 |
| Amantadine | none listed | 0 |
| Sumatriptan | none listed | 1 |
| Testosterone undecanoate | none listed | 2 |
| Miltefosine | none listed | 0 |
| Alprostadil | none listed | 2 |
| Oxymorphone | Ends 2029 (patent) | 0 |
| Testosterone enanthate | none listed | 1 |
| Isosorbide dinitrate | none listed | 0 |
| Histrelin | none listed | 0 |
| Methocarbamol | none listed | 1 |
| Molindone | none listed | 0 |
| Frovatriptan | none listed | 0 |
| Valrubicin | none listed | 0 |
| Fomepizole | Ends 2027 (patent) | 3 |
| Anisotropine | none listed | 0 |
| Penbutolol | none listed | 2 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| AR Androgen receptor | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Endo needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 5 trials led
- Bones, joints and muscles: 4 trials led
- Skin and connective tissue: 3 trials led